药师主导的治疗性碳水化合物限制治疗2型糖尿病:Pharm-TCR随机对照试验方案
本研究为社区随机对照试验方案,计划纳入200例30-75岁、BMI≥30、正在使用降糖药的2型糖尿病患者,随机分为药师主导的治疗性碳水化合物限制组(Pharm-TCR)或指南常规治疗组(TAU)。Pharm-TCR组接受12周极低碳水化合物、限制热量的商业饮食计划,由药师和生活方式教练指导,药师与家庭医生协作管理药物。主要结局是降糖药物使用的二分类指标,次要结局包括A1C、人体测量学和临床血液标志物。
要点
- Pharm-TCR组接受12周极低碳水化合物、限制热量的商业饮食计划,药师负责药物管理。
- 主要结局为降糖药物使用的二分类指标,次要结局包括A1C、人体测量学和血液标志物。
- 研究旨在评估社区药师主导的治疗性碳水化合物限制是否安全有效地减少或消除降糖药物需求。
核心结论
- 该随机对照试验旨在确定社区药师参与是否是一种安全有效的方式,以提供治疗性碳水化合物限制并减少/消除2型糖尿病患者对降糖药物的需求。
研究设计与样本
- 社区随机对照试验,实用型设计,平行分组,计划样本量N=200。
- 参与者随机等概率分配至药师主导的治疗性碳水化合物限制(Pharm-TCR)饮食组或指南常规治疗(TAU)组。
- Pharm-TCR组接受12周极低碳水化合物、限制热量的商业饮食计划,由药师和生活方式教练指导,药师与参与者家庭医生协作管理药物。
- 主要纳入标准:诊断为2型糖尿病、目前使用降糖药物治疗、年龄30-75岁、体重指数≥30。
- 主要结局为降糖药物使用的二分类指标;次要结局包括A1C、人体测量学和临床血液标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current treatment paradigm for type 2 diabetes mellitus (T2D) typically involves use of multiple medications to lower glucose levels in hope of reducing long-term complications. However, such treatment does not necessarily address the underlying pathophysiology of the disease and very few patients achieve partial, complete, or prolonged remission of T2D after diagnosis. The therapeutic potential of nutrition has been highlighted recently based on results of clinical trials reporting remission of T2D with targeted dietary approaches. During the initial phase of such interventions that restrict carbohydrates and/or induce rapid weight loss, hypoglycemia presents a notable risk to patients. We therefore hypothesized that delivering very low-carbohydrate, low-calorie therapeutic nutrition through community pharmacies would be an innovative strategy to facilitate lowering of glycated hemoglobin (A1C) while safely reducing the use of glucose-lowering medications in T2D. METHODS: A community-based randomized controlled trial that is pragmatic in nature, following a parallel-group design will be conducted (N = 200). Participants will have an equal chance of being randomized to either a pharmacist-led, therapeutic carbohydrate restricted (Pharm-TCR) diet or guideline-based treatment as usual (TAU). Pharm-TCR involves a 12-week very low carbohydrate, calorie-restricted commercial diet plan led by pharmacists and lifestyle coaches with pharmacists responsible for managing medications in collaboration with the participants' family physicians. Main inclusion criteria are diagnosis of T2D, currently treated with glucose-lowering medications, age 30-75 years, and body mass index ≥ 30. The primary outcome is a binary measure of use of glucose-lowering medication. Secondary outcomes include A1C, anthropometrics and clinical blood markers. DISCUSSION: There are inherent risks involved if patients with T2D who take glucose-lowering medications follow very low carbohydrate diets. This randomized controlled trial aims to determine whether engaging community pharmacists is a safe and effective way to deliver therapeutic carbohydrate restriction and reduce/eliminate the need for glucose-lowering medications in people with T2D. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03181165. Registered on 8 June 2017.
引用
- Durrer C, McKelvey S, Singer J, et al. Pharmacist-led therapeutic carbohydrate restriction as a treatment strategy for type 2 diabetes: the Pharm-TCR randomized controlled trial protocol. Trials. 2019. PMID: 31881991. doi:10.1186/s13063-019-3873-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。